• BONESUPPORT

  Led · Equity · Oct 2016

  Bonesupport develops Cerament, a radiopaque injectable osteoconductive bioceramic platform that remodels to host bone over six to twelve months and treats bone voids from trauma, infection, disease, or surgery. Its lead product, Cerament BVF, aims to avoid hospital readmissions and revision surgery caused by failed bone healing and residual bone voids. The company also offers CE‑marked antibiotic‑eluting variants, Cerament G and Cerament V, which provide local high initial antibiotic concentrations followed by sustained dosing above MIC. Cerament products are commercially available in the U.S., EU, SE Asia and the Middle East. Bonesupport recently received FDA approval to begin an IDE study with Cerament G, with the first patient expected before the end of 2016. The company intends to use new funds to drive Cerament sales in existing and new markets, generate further clinical data, and continue building its product pipeline. Bonesupport develops and sells Cerament, an injectable synthetic bone substitute used in orthopedic trauma, bone infections and instrument augmentation. Cerament is clinically shown to remodel into bone within 6–12 months. The CERAMENT™|G formulation is the first CE-marked injectable gentamicin antibiotic‑eluting ceramic bone graft substitute and is indicated for managing osteomyelitis in CE-marked countries (it is not available in the United States). Founded in 1999 by Lloyd Diamond and Oern R. Stuge, the company is headquartered in Lund, Sweden and has subsidiaries in the US and Germany. Bonesupport intends to use the funds to grow global sales and marketing and to accelerate expansion of the CERAMENT platform. The article reports the company closed a $14M financing in April 2015. BONESUPPORT develops injectable bone substitutes, with its CERAMENT™ platform commercially available in the U.S. and Europe for treatment of fragility and other fractures. The company focuses on orthopedic trauma, bone infection, instrument augmentation related to orthopedic surgery and spinal applications. It intends to use newly raised capital to accelerate commercial expansion in the US, Europe and Asia and to support the upcoming launch of an antibiotic‑formulated CERAMENT. BONESUPPORT also plans to further drive research and development and widen its product offerings. The company was founded in 1999 and is led by CEO Lloyd Diamond and Executive Chairman Oern Stuge, and it has subsidiaries in the US and Germany. Financially, it completed a second and final tranche of financing after having raised approximately SEK101m in 2011. BONESUPPORT develops CERAMENT, a ceramic‑like, non‑toxic, tissue‑friendly material that remodels into bone and is used to heal vertebral compression fractures and reinforce osteoporotic femoral necks. The company is pursuing ongoing product development including prophylaxis of hip fractures and combinations with antibiotics for prophylaxis or treatment of orthopedic infections. It intends to use the new funding to continue expanding and further developing its pipeline of products. BONESUPPORT was founded in 1999 by CEO Lars Lidgren and is headquartered at Ideon Science Park in Lund, Sweden. The company has over 30 employees and maintains subsidiaries in the United States, the Netherlands and Germany. The article reports the recent SEK120m raise to support these development and expansion plans.

No current team members are available.